BAX and central nervous system cancer: Decrease in C6 glioma cells in dose dependent manner was reported in an in vitro study when cells were treated with doses ranging 50, 100, 200 and 500 μg/mL with downregulation of Bcl-2, upregulation of Bax, and increased expression of apoptotic markers Caspase-3 and -9 (197).